A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 2015;131:e29-322
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014;13:26
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008;39:2052-8
   PubMed Web of Science ®Google Scholar
• Matsuzaki M, Yokoyama M, Saito Y, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009;73:1283-90
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
   PubMed Web of Science ®Google Scholar
• Blaha MJ, Martin SS. How do statins work?: changing paradigms with implications for statin allocation. J Am Coll Cardiol 2013;62:2392-4
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67
   PubMed Web of Science ®Google Scholar
• Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 2015;242:357-66
   PubMed Web of Science ®Google Scholar
• Tanaka N, Ishida T, Nagao M, et al. Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis 2014;237:577-83
   PubMed Web of Science ®Google Scholar
• Epadel [package insert, 2015 and pharmaceutical interview form, 2013]. Tokyo, Japan: Mochida Pharmaceutical Co., Ltd; 2015
   Google Scholar
• Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2015
   Google Scholar
• Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011;13:474-83
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Glickstein SB, Rowe JD, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012;6:5-18
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-90
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110:984-92
   PubMed Web of Science ®Google Scholar
• Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013
   Google Scholar
• Epanova [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014
   Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 report on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease in adults: full panel report supplement [online supplement]. Circulation 2014;129
   Google Scholar
• Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: A systematic evidence review for the U.S. preventive services task force. Evidence synthesis No. 131. Rockville, MD : Agency for Healthcare Reseach and Quality; 2015
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Magnuson EA, Farkouh ME, Fuster V, et al. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation 2013;127:820-31
   PubMed Web of Science ®Google Scholar
• Cohen DJ, Osnabrugge RL, Magnuson EA, et al. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2014;130:1146-57
   PubMed Web of Science ®Google Scholar
• Dieleman JP, van Wyk JT, van Wijk MA, et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin 2005;21:1461-8
   PubMed Web of Science ®Google Scholar
• Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 2011;18:99-107
   PubMed Web of Science ®Google Scholar
• Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med 2014;126:7-18
   PubMed Web of Science ®Google Scholar
• Braeckman R, Bays HE, Ballantyne CM, et al. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract 19343]. Circulation 2013;128:A19343
   Web of Science ®Google Scholar
• Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110-15
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang Z, Ayala C, et al. Costs of hospitalizations with a primary diagnosis of acute myocardial infarction among patients aged 18–64 years in the United States. In: Gaze DC, editor. Ischemic heart disease. Rijeka, Croatia: InTech; 2013. p 77-90
   Google Scholar
• Azoulay A, Pilote L, Filion KB, et al. Costs of treatment of acute myocardial infarction in Canadian and US hospitals. Cardiovasc Rev Rep 2003;24
   Google Scholar
• Cowie MR, Cure S, Bianic F, et al. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. Eur J Heart Fail 2011;13:681-9
   PubMed Web of Science ®Google Scholar
• Kongnakorn T, Ward A, Roberts CS, et al. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health 2009;12:880-7
   PubMed Web of Science ®Google Scholar
• Bloom BS, Tibi-Levy Y, Harari A, et al. Direct medical care costs of unstable angina pectoris in a defined population. J Managed Care Pharm 1999;5:39-44
   Google Scholar
• Osnabrugge RL, Speir AM, Head SJ, et al. Prediction of costs and length of stay in coronary artery bypass grafting. Ann Thorac Surg 2014;98:1286-93
   PubMed Web of Science ®Google Scholar
• Brown PP, Kugelmass AD, Cohen DJ, et al. The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. Ann Thorac Surg 2008;85:1980-6
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ, Filion KB, Azoulay A, et al. Outcomes and cost of coronary artery bypass graft surgery in the United States and Canada. Arch Intern Med 2005;165:1506-13
   PubMedGoogle Scholar
• Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015;314:142-50
   PubMed Web of Science ®Google Scholar
• Luengo-Fernandez R, Gray AM, Bull L, et al. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology 2013;81:1588-95
   PubMed Web of Science ®Google Scholar
• McConnachie A, Walker A, Robertson M, et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J 2014;35:290-8
   PubMed Web of Science ®Google Scholar
• Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation 2014;129:2329-45
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63
   PubMed Web of Science ®Google Scholar
• Superko HR, Superko SM, Nasir K, et al. Omega-3 fatty acid blood levels: clinical significance and controversy. Circulation 2013;128:2154-61
   PubMed Web of Science ®Google Scholar
• Macchia A, Romero M, D’Ettorre A, et al. Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study. PLoS One 2013;8:e62772
   Web of Science ®Google Scholar
• The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-8
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18
   PubMed Web of Science ®Google Scholar
• Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-9
   PubMed Web of Science ®Google Scholar
• Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis 2013;230:381-9
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Cannon C, Blazing M, et al. Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS [abstract]. J Am Coll Cardiol 2015;65:A4
   Google Scholar
• Kitamura A, Sato S, Kiyama M, et al. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol 2008;52:71-9
   PubMed Web of Science ®Google Scholar
• Iso H. A Japanese health success story: trends in cardiovascular diseases, their risk factors, and the contribution of public health and personalized approaches. EPMA J 2011;2:49-57
   PubMedGoogle Scholar
• Michailov GV, Davies GM, Krobot KJ. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. Eur J Health Econ 2012;13:365-74
   PubMed Web of Science ®Google Scholar
• A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). http://clinicaltrials.gov/show/NCT01492361. Accessed June 20, 2016
   Google Scholar